The Glimpse Group (VRAR) Q3 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Lyron Bentovim - Chairman of the Board, President & CEOMaydan Rothblum - Co-Founder, CFO, COO, Secretary, Treasurer & Non Independent Director Operator Welcome to the Glimps Group's Third Quarter Fiscal Year twenty twenty five Financial Results Webinar. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being ...

ImmuCell (ICCC) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Joe Diaz - Managing PartnerMichael Brigham - President, CEO & DirectorTimothy Fiori - CFOGeorge Melas-Kyriazi - PresidentRussell Tolander - Managing Director Conference Call Participants None - Analyst Operator Good morning, and welcome to the Innucel Corporation report First Quarter Ended 03/31/2025 Audited Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there wil ...

Logistic Properties of the Americas (LPA) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Camilo Ulloa - Investor RelationsEsteban Saldarriaga - CEOPaul Smith - CFOAndre Mazini - Head of Latam Research Operator Good morning, and welcome to LPA's First Quarter twenty twenty five Earnings Conference Call. My name is Audra, and I will be your operator for today's call. At this time, all participants are in a listen only mode. And please note that this call is being recorded. There will be a ...

STERIS (STE) Q4 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Julie Winter - Vice President of Investor Relations & Corporate CommunicationsMichael Tokich - Senior VP & CFODaniel Carestio - President, CEO & DirectorPatrick Wood - Managing DirectorMac Etoch - Senior Research Associate Conference Call Participants David Turkaly - Research AnalystMike Matson - Senior Equity Research AnalystMichael Polark - Senior Equity Research AnalystJason Bednar - Senior Research AnalystBrett Fishbin - Vi ...

Fidelis Insurance Holdings (FIHL) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Miranda Hunter - Head - Investor RelationsDaniel Burrows - Group CEO & Executive DirectorAllan Decleir - Group CFO & Bermuda CEOAndrew Andersen - Equity Research Vice PresidentLeon Cooperman - Chairman and CEOMatthew Carletti - Managing DirectorJonny Strickle - Group Managing DirectorMeyer Shields - Managing DirectorPablo Singzon - Executive Director Conference Call Participants Brian Meredith - AnalystDavi ...

Lantern Pharma (LTRN) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Panna Sharma - President, Chief Executive Officer & DirectorDavid Margrave - CFO & Secretary Conference Call Participants None - Analyst Operator Good morning, and welcome to our first quarter twenty twenty five earnings call. As a reminder, this call is being recorded, and all attendees are in a listen only mode. We will open the call for questions and answers after our management's presentation. A webcast replay of t ...

IM Cannabis (IMCC) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Anna Taranko - Director - Investor & Public RelationsOren Shuster - CEO & ChairmanUri Birenberg - Chief Financial Officer Conference Call Participants None - Analyst Operator Good morning, and welcome to I'm Cannabis' First Quarter twenty twenty five Earnings Conference Call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko, Director of Investor and public r ...

Financial Data and Key Metrics Changes - Adjusted profit before tax for Q1 2025 was $96 million, up 42% year-over-year, with revenues growing 28% to $467 million [6][10][18] - Reported return on equity increased to 29%, up six percentage points year-over-year [10] - Adjusted diluted EPS rose to 91¢ per share, reflecting a 32% increase year-over-year [19] Business Line Data and Key Metrics Changes - Clearing revenue grew 18% to $119 million, driven by higher net interest income despite lower average Fed fund rates [20] - Agency and execution revenue surged 42% to $240 million, with securities revenue increasing 59% to $151 million [20][21] - Energy revenue rose 20% to $88 million, benefiting from record volumes and strong demand [21] - Market making revenue grew 27% to $53 million, with security revenues doubling [22] Market Data and Key Metrics Changes - Exchange volumes in Q1 were up 15% year-over-year and 12% compared to Q4 [7] - Average daily value at risk remained low at $3.4 million, indicating effective market risk management [22] - Average balances increased to $17.1 billion, up from $11.3 billion a year ago, reflecting growth in client balances [23] Company Strategy and Development Direction - The company aims to generate reliable earnings growth across cycles by servicing client flow and gaining market share [14] - There is a focus on expanding the prime services offering and enhancing margins in the agency and execution segment [36][41] - The company is actively evaluating M&A opportunities while maintaining strict discipline to meet return targets [32][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the firm's operational resilience and ability to convert higher volumes into revenue and profit growth [30] - The company anticipates continued momentum for the rest of the year, despite potential risks from falling interest rates [31] - Management noted that client health remains strong, with minimal liquidity pressure observed during recent volatility [74][78] Other Important Information - The company successfully executed a $500 million senior notes issuance to enhance liquidity [9][17] - A dividend increase to 15¢ per share was announced for Q1 2025, up from 14¢ in 2024 [10][29] - The firm maintains a strong capital and liquidity position, with total funding increasing to $4.3 billion [28] Q&A Session Summary Question: Insights on the Prime business and its recent performance - Management noted a significant pickup in prime services, indicating unmet demand has been captured, but growth rates may slow [36][37] Question: Contribution from the Arna acquisition - The Arna acquisition closed at the end of Q1, with minimal contribution in the quarter, but early performance in April met expectations [42][43] Question: Divergence between cleared volume growth and commission revenue growth - Management explained that the previous year's unusually positive environment in agriculture affected year-over-year comparisons, but no pricing pressure was noted [48][51] Question: Client clearing balances growth - Average balances grew significantly, driven by increased house liquidity and client onboarding, with expectations for continued growth [59][62] Question: M&A appetite and activity - The company remains active in pursuing acquisitions, with a disciplined approach to ensure target returns are met [66][68] Question: Client health and potential risks - Management reported strong client performance with minimal stress observed, despite recent volatility [74][78] Question: Front office headcount changes - Some remapping of headcount occurred, particularly in the agriculture business, but overall growth and investment in clearing remain strong [80][82]

Financial Data and Key Metrics Changes - Total reported revenue grew by 4%, while constant currency organic revenue increased by 6% driven by volume and a 20 basis points price increase [6][10] - Gross margin increased by 170 basis points to 44.3%, with positive pricing, favorable mix, and productivity outpacing labor inflation [6][7] - EBIT margin rose by 110 basis points to 24.8% of revenue compared to the previous year [7] - Net income from continuing operations was $270 million, and adjusted earnings per diluted share increased by 14% to $2.74 [7][10] - Free cash flow for fiscal 2025 reached a record $787 million, significantly above guidance due to working capital improvements [8] Business Line Data and Key Metrics Changes - Healthcare constant currency organic revenue grew by 6% for the year, driven by strong recurring revenue streams, while capital equipment revenue declined by 5% [10][11] - Capital equipment orders grew over 12% for the full year, indicating strong underlying demand [11] - AST constant currency organic revenue grew by 9% for the year, with services growing by 7% [12] - Life Sciences saw a 1% increase in constant currency organic revenue, with margins improving to 42.3% [13] Market Data and Key Metrics Changes - The diversified nature of the business allowed the company to deliver results in line with original outlook despite obstacles [10] - The company anticipates revenue growth of 6% to 7% for fiscal 2026 across all segments, with a minor note on AST reflecting high single-digit growth in services [14][15] Company Strategy and Development Direction - The company plans to leverage its strengths to mitigate tariff exposure, with an estimated $30 million impact from tariffs included in the fiscal 2026 outlook [17][18] - The company is well-positioned to deliver both top and bottom line growth in 2026, with no acquisition or divestiture impacts expected [14][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver growth, particularly in recurring revenues and capital equipment orders, despite previous uncertainties in the pharma sector [23][24] - The anticipated tariff impact is expected to be managed strategically, with a focus on mitigating exposure through supply chain adjustments [18][62] Other Important Information - Capital expenditures for fiscal 2025 totaled $370 million, while depreciation and amortization amounted to $476 million [8] - The effective tax rate is planned at approximately 23.5% for fiscal 2026 [18] Q&A Session Summary Question: Comfort in Life Sciences bouncing back to 6% to 7% range - Management noted strong performance in recurring revenues, particularly in consumables, and a rebound in capital equipment orders towards the end of the year [23] Question: Impact of tariffs on EPS - Management discussed various headwinds and tailwinds, including $20 million in restructuring cost savings and lower interest expenses offsetting higher tax rates and tariff impacts [25][26] Question: Cash flow guidance differences - The anticipated $40 million legal settlement for ETO negatively impacts cash flow, along with tariffs and reduced inventory improvements [30] Question: M&A opportunities - Management indicated capacity for M&A from both financial and intellectual perspectives, should the right opportunity arise [32] Question: Onshoring trends - Management suggested that while there are opportunities for onshoring, regulatory complexities may limit rapid shifts in production [36][37] Question: AST growth expectations - Management expressed confidence in accommodating industry growth without capacity constraints [73] Question: Tariff breakdown and mitigation - Management confirmed that the $30 million tariff impact is a net number, with half attributed to China and half to global tariffs, and emphasized ongoing mitigation efforts [58][62]

Lantern Pharma (LTRN) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Speaker0 Good morning, and welcome to our first quarter twenty twenty five earnings call. As a reminder, this call is being recorded, and all attendees are in a listen only mode. We will open the call for questions and answers after our management's presentation. A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call. We issued a press release before the market opened today ...